Abstract
In a study of 258 moderately neutropenic HIV-infected patients, Filgrastim (recombinant methionyl human granulocyte colony-stimulating factor) treatment significantly reduced the incidence of severe neutropenia and bacterial infections. Filgrastim-treated patients also had 54% fewer severe bacterial infections and 45% fewer days in hospital for any bacterial infections. No unexpected or new adverse events were observed and there were no differences in plasma HIV-1 RNA levels between the groups.
Publication types
-
Clinical Trial
-
Multicenter Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acquired Immunodeficiency Syndrome / complications*
-
Acquired Immunodeficiency Syndrome / drug therapy
-
Adult
-
Aged
-
Bacterial Infections / etiology*
-
Bacterial Infections / prevention & control
-
Filgrastim
-
Granulocyte Colony-Stimulating Factor / adverse effects
-
Granulocyte Colony-Stimulating Factor / therapeutic use*
-
HIV-1*
-
Humans
-
Male
-
Middle Aged
-
Neutropenia / etiology*
-
Neutropenia / prevention & control
-
Prospective Studies
-
Recombinant Proteins
Substances
-
Recombinant Proteins
-
Granulocyte Colony-Stimulating Factor
-
Filgrastim